Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of May 2026, with a specific report date of May 5, 2026. The filing serves to disseminate a press release regarding an upcoming podium presentation at the AHNS 12th International Conference on Head and Neck Cancer. The presentation will showcase study results for the Company's Alpha DaRT® Head and Neck Cancer combination therapy with Pembrolizumab.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
No material changes to financial performance or operational status are reported in this document. The filing focuses exclusively on the announcement of a clinical study presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company is highlighting its clinical progress through the upcoming presentation of Alpha DaRT® combination therapy results.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information furnished is not "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific new risks or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the date and location of the AHNS 12th International Conference on Head and Neck Cancer.
- Review the full text of the attached press release (Exhibit 99.1) for specific clinical data points regarding the Alpha DaRT® and Pembrolizumab combination.
- Confirm the regulatory status of the Alpha DaRT® therapy in relevant jurisdictions.
- Check subsequent filings for the actual outcomes of the podium presentation.